PMGC Holdings (ELAB) Return on Capital Employed (2023 - 2026)
PMGC Holdings (ELAB) posted Return on Capital Employed of 98.12% for Q1 2026, down 115.05% sequentially from 45.63% in Q4 2025, and down 9737.0% YoY from 1.02% in Q1 2025.
PMGC Holdings (ELAB) Return on Capital Employed (2023 - 2026) Analysis & Trends
PMGC Holdings has reported Return on Capital Employed for 4 years, with the latest figure at 98.12% in Q1 2026.
- Quarterly Return on Capital Employed fell 9737.0% year-over-year to 98.12% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 98.12% (down 9737.0% YoY) and the FY2025 annual result came in at 98.47%, down 6321.0% from the prior year.
- Return on Capital Employed fell to 98.12% in Q1 2026 per ELAB's latest filing, from 45.63% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 15.3% in Q2 2025 and troughed at 182.42% in Q2 2024.
- A 4-year average of 55.03% and a median of 34.06% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed jumped 19772 bps in 2025, then plunged 9737 bps in 2026.
- Over 4 years, Return on Capital Employed stood at 0.48% in 2023, then tumbled by 4634 bps to 22.49% in 2024, then plunged by 103 bps to 45.63% in 2025, then tumbled by 115 bps to 98.12% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 98.12%, 45.63%, and 1.02% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | -74.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -98.12% |
| Dec 31, 2025 | -45.63% |
| Sep 30, 2025 | 1.02% |
| Jun 30, 2025 | 15.30% |
| Mar 31, 2025 | -0.75% |
| Dec 31, 2024 | -22.49% |
| Sep 30, 2024 | -84.71% |
| Jun 30, 2024 | -182.42% |
| Mar 31, 2024 | -132.05% |
| Dec 31, 2023 | -0.48% |